Yi‐Long Wu

Research interests

Publications

• Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2304594

• COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30314-4

• Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2027071

• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(18)32409-7

• Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30608-3

• Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30729-5

• First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

  The Lancet · 2017 · 10.1016/s0140-6736(17)30123-x

• The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

  Journal of Thoracic Oncology · 2016 · https://doi.org/10.1016/j.jtho.2015.09.009

• Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

  Clinical Cancer Research · 2016 · 10.1158/1078-0432.ccr-16-2554

• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1612674

• Lung cancer: current therapies and new targeted treatments

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)30958-8

• The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

  Journal of Thoracic Oncology · 2016 · 10.1016/j.jtho.2016.03.025

• Global cancer surgery: delivering safe, affordable, and timely cancer surgery

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00223-5

• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(14)71173-8

• Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00026-1

• The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

  Journal of Thoracic Oncology · 2015 · 10.1097/jto.0000000000000559

• First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

  Annals of Oncology · 2015 · 10.1093/annonc/mdv270

• The International Association for the Study of Lung Cancer Lung Cancer Staging Project

  Journal of Thoracic Oncology · 2015 · 10.1097/jto.0000000000000678

• First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1408440

• Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(13)70604-1

• Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1214886

• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70184-x

• Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.33.4235

• Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

  Cancer Cell · 2010 · 10.1016/j.ccr.2009.11.022

• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0810699

• Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

  The Lancet · 2009 · 10.1016/s0140-6736(09)61497-5

• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

  The Lancet · 2008 · 10.1016/s0140-6736(08)61758-4

Current projects

No projects listed.